Physician profile
Robin A Matuk
NPI 1245320563
$5,461.76
in general payments reported to CMS, 2019-2025
34 companies · $839 in 2025
The $839 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $799 · 2020: $260 · 2021: $753 · 2022: $846 · 2023: $1,143 · 2024: $820 · 2025: $839.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,802.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,586.69 | 2019-2025 | |
| Boston Scientific Corporation | $930.40 | 2019-2024 | Exalt Model D, Apollo Esg Nxt System, Axios |
| Janssen Biotech, INC. | $410.78 | 2019-2025 | Tremfya, Simponi, Stelara |
| Celgene Corporation | $394.50 | 2021-2023 | Zeposia |
| Gilead Sciences, INC. | $295.44 | 2019-2025 | Livdelzi |
| Daiichi Sankyo INC. | $263.87 | 2019-2023 | Injectafer |
| E.R. Squibb & Sons, L.L.C. | $228.97 | 2022-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $175.17 | 2019-2025 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $171.16 | 2019-2025 | Ocaliva |
| Takeda Pharmaceuticals U.S.A., INC. | $153.44 | 2019-2025 | Entyvio |
| Nestle Healthcare Nutrition INC. | $85.95 | 2020-2022 | |
| Shionogi INC | $81.96 | 2019-2020 | |
| Madrigal Pharmaceuticals | $81.92 | 2024-2025 | Rezdiffra, Resmetirom |
| Ipsen Biopharmaceuticals, INC | $75.24 | 2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $69.52 | 2021-2023 | Dificid |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $63.60 | 2022-2023 | |
| Biosense Webster, INC. | $59.36 | 2022 | |
| Phathom Pharmaceuticals, INC. | $58.41 | 2025 | Voquezna |
| Aimmune Therapeutics, INC. | $31.24 | 2024 | |
| Ironwood Pharmaceuticals, INC | $25.98 | 2020 | |
| Ardelyx, INC. | $24.49 | 2022 | |
| Evoke Pharma, INC. | $22.16 | 2021 | |
| Lilly USA, LLC | $17.71 | 2024 | Omvoh |
| Echosens North America, INC. | $17.35 | 2020 | |
| Ferring Pharmaceuticals INC. | $16.79 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $16.40 | 2022 | |
| Redhill Biopharma INC. | $15.44 | 2022 | |
| Olympus America INC. | $14.70 | 2024 | Evis X1 Video System Center |
| Alfasigma USA, INC. | $13.50 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $13.43 | 2019 | |
| Capsovision, INC. | $12.78 | 2023 | Capsocam Plus |
| Braintree Laboratories, INC. | $12.67 | 2021 | |
| Allergan, INC. | $11.65 | 2019 | |
| Alafair Biosciences, INC. | $9.09 | 2025 | Versawrap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Matuk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.